- Home
- NFJ vs RAPP Comparison
NFJ vs RAPP Comparison
Compare NFJ & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NFJ | RAPP |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NFJ | RAPP |
|---|---|---|
| Price | $14.23 | $25.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $68.29 |
| AVG Volume (30 Days) | 332.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.25 | $22.06 |
| 52 Week High | $15.75 | $52.93 |
Technical Indicators
Market Signals| Indicator | NFJ | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 39.47 |
| Support Level | $14.14 | N/A |
| Resistance Level | $15.20 | $31.49 |
| Average True Range (ATR) | 0.20 | 2.51 |
| MACD | -0.03 | 0.30 |
| Stochastic Oscillator | 10.46 | 38.05 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.